New combo aims to revive immunotherapy in stubborn tumors
Disease control
Not yet recruiting
This early-phase study tests whether adding a drug called 5-Azacitidine can help standard immunotherapies work again in people with advanced solid tumors that no longer respond to PD-1 or PD-L1 inhibitors. About 35 adults with certain types of cancer will receive the combination …
Phase: PHASE1 • Sponsor: Mohammed Milhem • Aim: Disease control
Last updated May 14, 2026 12:04 UTC